The central goal of this Core Resource is to maintain and provide a research of pathology documented and extended pancreatic cancer prone families that can be made available to investigators within the SPORE and from other SPOREs for their individual research projects. This registry of families and repository for frozen lymphocytes and serum that has been obtained from pancreatic cancer affected family members is housed at Creighton University's Hereditary Cancer Institute. In an ongoing collaboration with the oncology units at Creighton University, the University of Nebraska Medical Center, Duke University, Durham, NC and M D Anderson Cancer Center, Houston, TX, additional pancreatic cancer prone families will be accrued by interviewing a consecutive series of pancreatic cancer patients to determine their family cancer histories. Family histories will be extended by paying special attention to medical, genetic, pathology, and natural history features, as well as environmental carcinogens. In addition, the molecular biology laboratory at Creighton will prepare and archive lymphocyte and pancreatic tissue DNA. This will function in conjunction with Scott Kern, M.D., from Johns Hopkins University, toward the identification of new genes important in pancreatic tumorigenesis (mutations of p16 already identified by Dr. Kern in one of our families). Detailed analyses of pancreatic cancer pronce families are likely to provide important clues about the etiology and prevention of pancreatic cancer, which should harbor an important translational potential for patient benefit.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA072712-03S1
Application #
6217495
Study Section
Project Start
1999-03-25
Project End
2003-01-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
3
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Nebraska Medical Center
Department
Type
DUNS #
City
Omaha
State
NE
Country
United States
Zip Code
68198
Chan, June M; Gong, Zhihong; Holly, Elizabeth A et al. (2013) Dietary patterns and risk of pancreatic cancer in a large population-based case-control study in the San Francisco Bay Area. Nutr Cancer 65:157-64
Mutolo, Michael J; Morris, Kirsten J; Leir, Shih-Hsing et al. (2012) Tumor suppression by collagen XV is independent of the restin domain. Matrix Biol 31:285-9
Pour, Parviz M (2012) A novel tissue for islet transplantation in diabetics. Pancreatology 12:57-60
Sherman, Simon; Shats, Oleg; Ketcham, Marsha A et al. (2011) PCCR: Pancreatic Cancer Collaborative Registry. Cancer Inform 10:83-91
Chan, June M; Wang, Furong; Holly, Elizabeth A (2009) Sweets, sweetened beverages, and risk of pancreatic cancer in a large population-based case-control study. Cancer Causes Control 20:835-46
Moniaux, Nicolas; Nemos, Christophe; Deb, Shonali et al. (2009) The human RNA polymerase II-associated factor 1 (hPaf1): a new regulator of cell-cycle progression. PLoS One 4:e7077
Mimeault, M; Hauke, R; Batra, S K (2008) Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther 83:673-91
Hennig, R; Osman, T; Esposito, I et al. (2008) BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferation. Br J Cancer 99:1064-73
Davda, Jasmine P; Jain, Maneesh; Batra, Surinder K et al. (2008) A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs. Int Immunopharmacol 8:401-13
Hennig, Rene; Kehl, Timo; Noor, Seema et al. (2007) 15-lipoxygenase-1 production is lost in pancreatic cancer and overexpression of the gene inhibits tumor cell growth. Neoplasia 9:917-26

Showing the most recent 10 out of 108 publications